Galectin Therapeutics (GALT) Receives “Buy” Rating from HC Wainwright

Galectin Therapeutics (NASDAQ:GALT)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Thursday. They currently have a $10.00 price objective on the stock, up from their previous price objective of $6.00.

GALT has been the topic of several other reports. ValuEngine cut Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research raised Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research note on Thursday, November 30th. Roth Capital assumed coverage on Galectin Therapeutics in a research note on Thursday, October 19th. They set a “buy” rating and a $8.00 target price on the stock. Finally, Seaport Global Securities reaffirmed a “buy” rating and set a $5.00 target price on shares of Galectin Therapeutics in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. Galectin Therapeutics currently has an average rating of “Buy” and a consensus target price of $5.55.

Shares of Galectin Therapeutics (GALT) opened at $1.54 on Thursday. Galectin Therapeutics has a 52 week low of $0.87 and a 52 week high of $3.68.

Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings data on Tuesday, November 7th. The company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. research analysts predict that Galectin Therapeutics will post -0.52 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Galectin Therapeutics by 18.2% during the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock valued at $2,144,000 after buying an additional 134,165 shares during the last quarter. Advisor Group Inc. grew its stake in shares of Galectin Therapeutics by 7.4% during the third quarter. Advisor Group Inc. now owns 519,850 shares of the company’s stock valued at $1,112,000 after buying an additional 35,850 shares during the last quarter. Virtu KCG Holdings LLC grew its stake in shares of Galectin Therapeutics by 24.4% during the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock valued at $264,000 after buying an additional 21,008 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Galectin Therapeutics by 4.4% in the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after purchasing an additional 3,176 shares during the period. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/12/07/galectin-therapeutics-galt-receives-buy-rating-from-hc-wainwright.html.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply